STERIS plc (NYSE:STE) is reporting second quarter financial results on Monday 2nd November 2020, after market close.
According to analysts surveyed by Thomson Reuters, STE is expected to report 2Q21 income of $ 1.27 per share from revenue of $ 722.87 million.
For the full year, analysts anticipate top line of $ 3046.73 million, while looking forward to income of $ 5.77 per share bottom line.
Previous Quarter Performance
STERIS plc disclosed income for the first quarter of $ 1.31 per share, from the revenue of $ 668.93 million. The quarterly earnings escalated 6.50 percent while revenues shrunk 4.00 percent compared with the same quarter last year.
The consensus estimates are income of $ 0.96 per share from $ 635.98 million in revenue. The bottom line results beat street analysts by $ 0.35 or 36.46 percent, at the same time, top line results outshined analysts by $ 32.95 million or 5.18 percent.
Stock Performance
On Friday, shares of STERIS plc has traded high as $ 178.66 and has cracked $ 172.90 on the downward trend, reaching $ 177.19 with volume of 352.60 thousand shares.
According to the previous trading day, closing price of $ 177.19, representing a 67.78 % increase from the 52 week low of $ 105.69 and a 8.1 % decrease over the 52 week high of $ 192.97.
The company has a market capital of $ 15.07 billion and is part of the Healthcare sector and Medical Instruments & Supplies industry.
Recent Stock Dividend Announcement
On August 3, 2020, the board of directors authorized quarterly dividend of $ 0.03 per share to holders of record as of the close of business on August 27, 2020, with payment date of September 24, 2020 and ex-dividend date on August 26, 2020.
STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
